Literature DB >> 20372859

The enhanced transcriptional activity of the V-val subtype of Epstein-Barr virus nuclear antigen 1 in epithelial cell lines.

Shi-Juan Mai1, Dan Xie, Yu-Fan Huang, Feng-Wei Wang, Yi-Ji Liao, Hai-Xia Deng, Wen-Ju Liu, Wen-Feng Hua, Yi-Xin Zeng.   

Abstract

The Epstein-Barr virus encoded nuclear antigen 1 (EBNA1) is required for the replication and maintenance of the episomal EBV genome and for the transactivation of viral gene expression. EBNA1 has been classified into five subtypes, among which the V-val subtype was reported to be associated with nasopharyngeal carcinoma (NPC). Here we report a higher transcriptional activity of the V-val subtype of EBNA1 than for the prototype derived from B95.8 cells to transactivate FR-containing luciferase plasmid, which was mainly a consequence of the mutations in the carboxy-terminus of EBNA1. This interpretation was further supported by the finding that the variant form of EBNA1 has a higher binding affinity for the FR sequence than the prototype by electrophoretic mobility shift assays. The functional advantage of the V-val EBNA1 investigated in this study may contribute to the oncogenesis of NPC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20372859     DOI: 10.3892/or_00000779

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  3 in total

Review 1.  Epstein-barr virus sequence variation-biology and disease.

Authors:  Stelios Tzellos; Paul J Farrell
Journal:  Pathogens       Date:  2012-11-08

2.  Sequence Variation Analysis of Epstein-Barr Virus Nuclear Antigen 1 Gene in the Virus Associated Lymphomas of Northern China.

Authors:  Lingling Sun; Zhenzhen Zhao; Song Liu; Xia Liu; Zhifu Sun; Bing Luo
Journal:  PLoS One       Date:  2015-10-13       Impact factor: 3.240

3.  Carcinoma-risk variant of EBNA1 deregulates Epstein-Barr Virus episomal latency.

Authors:  Jayaraju Dheekollu; Kimberly Malecka; Andreas Wiedmer; Henri-Jacques Delecluse; Alan K S Chiang; Dario C Altieri; Troy E Messick; Paul M Lieberman
Journal:  Oncotarget       Date:  2017-01-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.